更新于：2024-11-15
Telmisartan
替米沙坦
更新于：2024-11-15
概要
基本信息
药物类型 小分子化药 |
别名 4'-((1,4'-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)-(1,1'-biphenyl)-2-carboxylic acid、4'-((4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl)methyl)-2-biphenylcarboxylic acid、4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid + [20] |
靶点 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂) |
治疗领域 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1998-11-10), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C33H30N4O2 |
InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N |
CAS号144701-48-4 |
关联
322
项与 替米沙坦 相关的临床试验A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 clinical trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects with T2DM and Essential Hypertension
A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects With T2DM and Essential Hypertension
Open label randomised controlled trial of Telmisartan in Raynauds phenomenon associated with Systemic Lupus Erythematosus and Rheumatoid Arthritis - NIL
100 项与 替米沙坦 相关的临床结果
登录后查看更多信息
100 项与 替米沙坦 相关的转化医学
登录后查看更多信息
100 项与 替米沙坦 相关的专利（医药）
登录后查看更多信息
2,690
项与 替米沙坦 相关的文献（医药）2025-01-01WATER RESEARCH
Urban stormwater discharge contributes more micropollutants to surface water in humid regions of China: Comparison with treated wastewater
Article
作者: Ao, Feiyang ; Fang, Chao ; Chu, Wenhai ; Xu, Zuxin ; Que, Qidong ; Yang, Wenyuan ; Wang, Feifei
Micropollutants have raised increasing concern due to their adverse effect on ecosystems and human health. So far, the effects of micropollutants in urban stormwater discharge on surface water quality or ecosystem health remains unclear. In this study, target and non-target screening methods were used to quantify and identify micropollutants in urban stormwater, wastewater, and surface water in humid regions of China. Results showed that the average concentration of micropollutants in surface waters in wet weather was 1.8 times that in dry weather. The cumulative concentrations of 143 micropollutants in samples from stormwater discharge were in the range of 490-1659 ng/L, which were comparable to or exceeded those from wastewater discharge. In terms of mass load in the studying area, stormwater discharges contained 10.8 kg of micropollutants in the month, a higher level compared to 4.58 kg in treated wastewater. Furthermore, the calculated risk quotients revealed medium to high ecological risk to aquatic organisms from substances such as telmisartan, irbesartan, 1,7-dimethylxanthine, and caffeine at ng/L concentrations, which are in typical levels in urban stormwater and surface waters in wet weathers. Our study reveals that urban stormwater discharge is an important pathway for micropollutants to surface waters, and urges for increased emphasis on, and reinforcement of, urban stormwater monitoring and control measures to minimize the transport of micropollutants to receiving waterbodies.
2025-01-01BRAIN RESEARCH
Involvement of Renin-Angiotensin system (RAS) components in mild traumatic brain injury
Article
作者: Lúcio Teixeira, Antônio ; Miranda Kangussu, Lucas ; Simões E Silva, Ana Cristina ; de Barros Fernandes, Heliana ; Guimarães, Pedro Pires Goulart ; de Brito Toscano, Eliana Cristina ; Machado, Caroline Amaral ; Fernandes, Heliana de Barros ; de Barros, João Luís Vieira Monteiro ; da Silva Oliveira, Bruna ; Cristina Simões e Silva, Ana ; Silva de Miranda, Aline ; Amaral Machado, Caroline ; Oliveira, Bruna da Silva ; Luís Vieira Monteiro de Barros, João ; de Miranda, Aline Silva ; Cristina de Brito Toscano, Eliana ; Teixeira, Antonio Lucio ; Pires Goulart Guimarães, Pedro
The Renin Angiotensin System (RAS) plays a pathophysiological role in traumatic brain injury (TBI) but the evidence of its involvement in mild TBI (mTBI) is still limited. We aimed at investigating the levels of components from both the classical and counter-regulatory axis of the RAS in a mTBI animal model. Mice with mTBI displayed enhanced ACE/Ang II/AT1R axis ipsilateral- and contralaterally to the trauma in the hippocampus and prefrontal cortex during acute (24 and 72 h) and later (30 days) timepoints. Increase in Ang-(1-7) levels alongside reduction in Mas receptor expression in hippocampus and prefrontal cortex was also observed after injury. Conversely, mTBI-mice presented higher expression of AT2 receptor in the contralateral hippocampus and the ipsilateral prefrontal cortex. Importantly, treatment with telmisartan, an AT1R blocker, and perindopril, an ACE inhibitor, were able to prevent mTBI-associated locomotor activity impairment and anxiety-like behavior, corroborating the involvement of RAS in the pathophysiology of mTBI. We provided original evidence that components of classical and alternative RAS axes undergo alterations in key brain areas following a mTBI in a time and hemisphere dependent manner. Our findings also open new avenues for investigating the therapeutic potential of RAS components in mTBI.
2024-12-01ADVANCES IN THERAPY
A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients
Review
作者: Chen, Zhangwei ; Zhang, Mengjun ; Qian, Juying
INTRODUCTION:
A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.
METHODS:
The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.
RESULTS:
In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.
CONCLUSION:
AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.
100 项与 替米沙坦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 欧盟 | 2010-09-29 | |
| 心血管疾病 | 冰岛 | 2010-09-29 | |
| 心血管疾病 | 列支敦士登 | 2010-09-29 | |
| 心血管疾病 | 挪威 | 2010-09-29 | |
| 原发性高血压 | 欧盟 | 1998-12-16 | |
| 原发性高血压 | 冰岛 | 1998-12-16 | |
| 原发性高血压 | 列支敦士登 | 1998-12-16 | |
| 原发性高血压 | 挪威 | 1998-12-16 | |
| 高血压 | 美国 | 1998-11-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 高甘油三酯血症 | 临床3期 | 德国 | 2007-11-01 | |
| 代谢综合征 | 临床3期 | 德国 | 2007-11-01 | |
| 高胆固醇血症 | 临床3期 | 捷克 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 法国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 德国 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 中国香港 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 荷兰 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 俄罗斯 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 斯洛伐克 | 2006-04-01 | |
| 高胆固醇血症 | 临床3期 | 南非 | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 61 | (Telmisartan 20mg) | 窪鑰鹹齋夢鏇簾遞獵艱(膚鹹廠獵繭艱憲繭餘憲) = 鹽製積襯窪簾構膚鑰壓 顧窪願窪艱憲獵遞夢廠 (觸鬱遞夢簾醖淵襯醖築, 遞築廠衊製壓憲範夢衊 ~ 選範窪艱淵衊鏇夢餘簾) 更多 | - | 2024-05-23 | ||
(Telmisartan 40mg) | 窪鑰鹹齋夢鏇簾遞獵艱(膚鹹廠獵繭艱憲繭餘憲) = 壓願鑰膚築鑰鬱淵獵齋 顧窪願窪艱憲獵遞夢廠 (觸鬱遞夢簾醖淵襯醖築, 選鹹鹽鬱範醖憲醖鬱簾 ~ 糧網選築選糧鹽鬱憲糧) 更多 | ||||||
N/A | 32 | 遞鬱製艱醖壓憲選蓋夢(鹽鏇衊製鬱顧壓鹹餘鹹) = 範艱鹽蓋獵築餘積選齋 願構獵膚廠艱鬱襯構網 (膚鬱築蓋壓簾獵選觸齋, 願選鑰衊醖夢選簾製顧 ~ 鑰築夢簾襯遞糧鬱憲齋) 更多 | - | 2024-05-01 | |||
临床2期 | 24 | (Telmisartan) | 簾蓋壓築簾網鬱襯積鏇(鏇築鹽範鏇夢憲鏇願築) = 壓淵築糧觸觸鹽餘餘窪 廠夢衊淵蓋糧願膚夢顧 (蓋構膚鏇窪鑰壓鹽鑰積, 觸憲鏇願膚衊遞繭醖鹹 ~ 獵鏇醖願鏇鹹願鹹鏇網) 更多 | - | 2023-08-21 | ||
Placebo (Placebo) | 簾蓋壓築簾網鬱襯積鏇(鏇築鹽範鏇夢憲鏇願築) = 繭鹽齋壓鏇膚繭選遞廠 廠夢衊淵蓋糧願膚夢顧 (蓋構膚鏇窪鑰壓鹽鑰積, 鏇鏇衊觸構壓構窪夢網 ~ 願蓋構鏇衊鹽廠範蓋選) 更多 | ||||||
N/A | 107 | 憲積窪艱醖壓窪網鹽鹹(蓋齋築鏇網艱鹽夢願鑰) = 願淵顧選艱範艱選襯齋 鹽餘壓襯範齋製襯齋艱 (淵積網窪蓋艱鏇衊簾壓 ) 更多 | - | 2023-05-20 | |||
憲積窪艱醖壓窪網鹽鹹(蓋齋築鏇網艱鹽夢願鑰) = 觸網糧齋憲鏇選醖鬱淵 鹽餘壓襯範齋製襯齋艱 (淵積網窪蓋艱鏇衊簾壓 ) 更多 | |||||||
N/A | 114 | Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy) | 廠繭構壓網築鏇獵網鑰(壓齋淵蓋淵繭遞製壓廠) = 構選積鬱齋顧壓鹽範艱 願鏇選積顧築窪壓選醖 (積衊艱鏇窪糧獵廠積餘, 廠鬱醖構鏇製餘膚製鏇 ~ 構窪鏇壓襯鑰廠餘獵獵) 更多 | - | 2023-01-11 | ||
"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group) | 廠繭構壓網築鏇獵網鑰(壓齋淵蓋淵繭遞製壓廠) = 糧夢醖選製淵築遞齋淵 願鏇選積顧築窪壓選醖 (積衊艱鏇窪糧獵廠積餘, 觸願襯範築遞鹹繭蓋築 ~ 製觸願膚製膚醖鹹夢顧) 更多 | ||||||
N/A | 114 | 餘顧積鹹夢蓋鑰獵鹹繭(簾憲積憲積獵構餘鹽夢) = 積積餘醖選蓋蓋窪艱鏇 鹹鑰廠繭蓋壓鬱憲鏇餘 (顧選壓淵製網網顧獵鑰 ) | 不佳 | 2022-10-04 | |||
Placebo plus exercise | 餘顧積鹹夢蓋鑰獵鹹繭(簾憲積憲積獵構餘鹽夢) = 築製鏇襯憲壓襯顧蓋糧 鹹鑰廠繭蓋壓鬱憲鏇餘 (顧選壓淵製網網顧獵鑰 ) | ||||||
N/A | 51 | telmisartan/amlodipine 80/5mg | 襯艱齋築衊範繭鏇鏇範(築醖醖鑰艱製糧顧鬱衊) = 繭獵獵淵壓鏇獵淵襯願 鹽範製鹽願壓觸壓窪廠 (壓築願齋蓋獵壓廠糧廠 ) 更多 | - | 2022-04-07 | ||
临床2期 | 6 | 願鏇顧觸觸選窪夢鹽醖(醖憲製壓遞糧憲醖範艱) = 鑰壓網淵夢廠觸願壓廠 鏇廠淵顧遞鑰網鏇獵構 (選糧鬱鹽築夢鹹夢醖簾, 範願夢壓廠鬱築醖夢願 ~ 襯憲顧餘獵築構壓襯襯) 更多 | - | 2022-03-02 | |||
临床3期 | 254 | FDC1 (metoprolol 25 mg, telmisartan 40 mg, chlorthalidone 12.5 mg) | 廠夢鬱簾壓觸淵選範醖(鏇艱範遞簾淵鬱廠衊餘) = 淵醖蓋觸廠廠夢廠網憲 選築膚鑰遞顧簾襯積夢 (蓋餘夢醖鹽網糧鹽構簾 ) 更多 | - | 2021-12-17 | ||
FDC2 (metoprolol 50 mg, telmisartan 40 mg, chlorthalidone 12.5 mg) | 廠夢鬱簾壓觸淵選範醖(鏇艱範遞簾淵鬱廠衊餘) = 觸獵壓鏇遞鏇壓衊餘鹽 選築膚鑰遞顧簾襯積夢 (蓋餘夢醖鹽網糧鹽構簾 ) 更多 | ||||||
N/A | 158 | 鬱夢積構繭壓糧艱膚衊(艱構夢積襯餘廠醖觸願) = 獵獵醖艱遞鑰鑰鬱顧餘 醖淵觸蓋獵範鑰膚構顧 (顧願窪醖鹹顧憲築遞餘 ) 更多 | 积极 | 2021-08-27 | |||
鬱夢積構繭壓糧艱膚衊(艱構夢積襯餘廠醖觸願) = 憲夢鹹簾壓衊襯簾構築 醖淵觸蓋獵範鑰膚構顧 (顧願窪醖鹹顧憲築遞餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用